Novavax Inc vs Global X Robo Global Robotics & Automation ETF — how do they compare? Novavax Inc trades at $7.96 (market cap $1.31B), while Global X Robo Global Robotics & Automation ETF trades at $84.55. The key difference: Global X Robo Global Robotics & Automation ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | ROBO | |
|---|---|---|
Market Cap | $1.31B | — |
Sector | Health | Sector/Thematic |
52-Week High | $11.19 | $90.34 |
52-Week Low | $6.22 | $62.34 |
Enterprise Value | $889.30M | — |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.
The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.
ROBO trades at $84.50, up 1.25% today, with a bullish technical signal from moving averages and a neutral stance from oscillators. Recent news highlights robotics stocks rallying, with thematic ETF interest growing in AI and automation. The stock shows strong momentum but lacks disclosed financial ratios, requiring deeper fundamental verification.
Outlook is cautiously optimistic due to sector tailwinds from AI infrastructure growth, but risks include cyclical exposure and high valuations. Investors should assess upcoming earnings for profitability metrics, as current data gaps limit fundamental clarity amid positive market sentiment.
Trailing returns across standard periods
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →